Page 2 - Blinded Evaluation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Balyasny Asset Management LLC acquired a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) during the third quarter, HoldingsChannel reports. The firm acquired 36,915 shares of the biopharmaceutical company’s stock, valued at approximately $1,319,000. Several other hedge funds and other institutional investors have also modified their holdings of the company. Bain Capital Public Equity […]

Jefferies Group LLC bought a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 72,500 shares of the biopharmaceutical company’s stock, valued at approximately $2,591,000. Other large investors also recently made changes to their […]

Investegate announcements from Infant Bacterial Therapeutics, A Blinded Evaluation of the Connection Study – Sustained Feeding Tolerance (SFT) Correlates to Clinical Outcomes